Each of these four Gulf markets has its own approval route: a Ministry of Health licence before any ad in Kuwait and Oman, NHRA Advertisement Committee review in Bahrain, and written sign-off by the medical director and the practitioner in Qatar. This page sets out each country's rules and how we work within them.
This is a working summary for marketing teams, not legal advice. Every rule below names the instrument it comes from so you can read the source rather than take our word for it, and so you can tell when something here has gone out of date.
Who regulates healthcare advertising in Qatar, Kuwait, Bahrain and Oman
- Qatar: Ministry of Public Health, Department of Healthcare Professions Circulars 01/2019 and 01/2021 (amended by 01/2022)
- Kuwait: MOH Ministerial Resolution 87 on medical advertisements in the private sector, Law 70/2020, and Ministerial Decision 9/2025 for health products
- Bahrain: NHRA Healthcare Professionals Guidelines for Advertising Health Services (2017) and Legislative Decree 21/2015
- Oman: MOH Health Advertisement Licence (DGPHE), MOCIIP Resolution 619/2022 and the Media Law (Royal Decree 58/2024)
- Data protection: Qatar Law 13/2016, Bahrain PDPL (Law 30/2018) and Oman PDPL (Royal Decree 6/2022). Kuwait has no general data-protection law.
More than one of these usually applies at once. A campaign can satisfy the advertising regulator and still breach the data-protection one, which is the failure mode that catches most practices: the creative gets reviewed and the tracking does not.
The rules that actually change what you can publish
- No approval, no publish. Map every asset to its approval route before production starts.
- Strip superlatives and guarantees everywhere. Kuwait, Bahrain and Oman ban named words, and Qatar applies a broad “professional dignity” test.
- Prices and offers need prior approval in Kuwait and Oman, and committee review in Bahrain.
- Where patient images or testimonials are used at all, they need written consent. Kuwait requires consent from the patient, the practitioner and clinic management. Oman, Qatar and Kuwait publish no express testimonial rule, so we treat testimonials there as restricted until the regulator confirms.
- Oman already requires influencers to hold a MOCIIP licence. Kuwait's Decree-Law 102/2026 introduces one from about April 2027. Qatar and Bahrain have none yet, but influencer posts are still health ads.
Qatar
Regulators: Ministry of Public Health (MOPH), Department of Healthcare Professions (DHP).
- We found no external MOPH ad permit, though this is unconfirmed. Every social-media post and ad must be approved in writing by both the facility's medical director and the practitioner, and both are liable (Circular 01/2021, amended by 01/2022).
- Advertise only MOPH-regulated services using MOPH-approved equipment and drugs, and no non-medical services.
- Credentials must match the DHP register exactly, and only the clinical privileges DHP has granted may be advertised.
- Practitioners may not promote themselves beyond professional dignity or lend their names to commercial promotion (Circular 01/2019).
- Patient images and video need consent, and imagery must respect Islamic culture and societal traditions.
- MOPH took legal action over 51 violating ads in 2023.
- Health data is special-nature data under Law 13/2016, and electronic marketing needs prior opt-in consent.
Kuwait
Regulators: Ministry of Health: Health Licensing Department and Drug Inspection Department.
- A licence from the MOH Health Licensing Department is required before any private-sector medical ad, including on social media (Ministerial Resolution 87).
- No service prices, discounts, offers or instalment plans without prior approval (Resolution 87; Law 70/2020).
- “The best”, “the only”, “guaranteed”, “legendary” and misleading information are banned.
- Filming patients needs written permission from the patient, the practitioner and clinic management.
- In April 2023 the MOH temporarily closed 33 cosmetic clinics over social-media advertising.
- Health-product ads need a Drug Inspection Department licence, with the licence number on the ad (Ministerial Decision 9/2025).
- From about April 2027, the Media Regulation Law (Decree-Law 102/2026) will require a Ministry of Information licence for anyone promoting goods or services to a Kuwaiti audience.
Bahrain
Regulators: National Health Regulatory Authority (NHRA) and its Advertisement Committee.
- The NHRA guideline names facilities, practitioners and advertising agencies, and covers social media and websites.
- The Advertisement Committee approves and monitors ads before or after publication. Whether prior approval is mandatory for every ad is unconfirmed, so we submit before launch.
- “The best”, “the first”, “the latest”, “the only”, “state of the art”, “guaranteed”, “sure cure” and comparisons between providers are banned (§2, §4).
- Testimonials are allowed if honest, scientifically supported and consented to before publication (§8).
- Prices must be exact and complete. Discounts and “free” offers are discouraged (§1, §5, §7, §11).
- Titles must match the NHRA licence, and doctors are responsible for their personal accounts.
- Health data is sensitive data under the PDPL (Law 30/2018), so we use explicit, written, revocable consent.
Oman
Regulators: Ministry of Health, Directorate General of Private Health Establishments; MOCIIP; Ministry of Information.
- An MOH Health Advertisement Licence is required before publishing any ad in any medium, and the approval number must be clearly shown on the ad.
- Each new or changed creative needs its own approval, and unlicensed ads go to a violation committee.
- “The best”, “the newest” and “the first” are banned, and so are images or wording that offend public morals or modesty.
- Offers and reduced prices need Ministry of Commerce/Consumer Protection approval first, attached to the MOH application.
- Paid promoters need a MOCIIP licence (Resolution 619/2022) shown on their posts, and may not promote services that lack approval. The clinic files an MOH influencer undertaking.
- The PDPL (Royal Decree 6/2022) has been fully enforceable since 5 Feb 2026, and processing health data needs an MTCIT permit.
At a glance: tactic by tactic
| Tactic | Qatar | Kuwait | Bahrain | Oman |
|---|---|---|---|---|
| Patient testimonials | Narrow exceptions | Narrow exceptions | Allowed with conditions | Narrow exceptions |
| Asking for and showing reviews | No rule found | No rule found | No rule found | No rule found |
| Before-and-after images | Narrow exceptions | Narrow exceptions | Narrow exceptions | Narrow exceptions |
| “Best”, “No.1” and guarantee claims | Narrow exceptions | Not permitted | Not permitted | Not permitted |
| Prices, discounts and offers | No rule found | Narrow exceptions | Narrow exceptions | Allowed with conditions |
| Influencers and endorsements | Narrow exceptions | Narrow exceptions | Allowed with conditions | Allowed with conditions |
| A doctor promoting their own practice | Narrow exceptions | Narrow exceptions | Narrow exceptions | No rule found |
| AI-generated content | No rule found | No rule found | No rule found | No rule found |
| Patient images and data | Narrow exceptions | Allowed with conditions | Allowed with conditions | Narrow exceptions |
| Regulator approval before publishing | Process | Process | Process | Process |
"No rule found" means the research found no published rule, not that the tactic is safe. We treat those as needing the regulator's approval.
How Branding Pioneers handles it
- No approval, no publish. Each asset is mapped to its approval route, and licence numbers go on the creative where required (Kuwait, Oman).
- In Qatar, posts carry written sign-off from the medical director and the practitioner before we schedule them.
- One banned-claims list for the region is checked against every caption and script.
- Patient content is off by default. When used, it has written, purpose- and time-limited consent, with no retouching or AI.
- We engage only licensed creators where a regime exists, and the health approval still applies on top.
- Our India team works from consented, de-identified or final-approved assets. Raw patient data stays in the client's in-country systems.
- We keep an approvals file for every asset and can take content down the same day.
Tracking deserves the same scrutiny as copy. Analytics, pixels and remarketing tags routinely collect more than a healthcare provider is permitted to share, and the default installation of most of them is not compliant in Qatar, Kuwait, Bahrain and Oman. Audit what your tags send before you audit your ad copy.
Before you run anything
- Can you substantiate every claim in the creative, today, from a document you can produce?
- Do you have written consent for every patient who appears, covering this specific use?
- Has the approval or licence this market requires been granted, and is its number on the creative where required?
- Does your tracking send anything that identifies a patient or their condition?
- Has someone qualified in Qatar, Kuwait, Bahrain and Oman reviewed the campaign, not just the marketing team?
If the answer to the last one is no, that is the gap worth closing first. We work inside these rules daily and will tell you when something you want to publish is not worth the exposure, but we are a marketing agency, and a regulated market deserves a qualified reviewer as well.
Not legal advice. A planning summary of published rules, last checked on 11 October 2026. Rules change, so confirm the current text with the regulator or local counsel before relying on it.
